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CURRENT STATE OF PRECISION THERAPY FOR THE MANAGEMENT OF 
LUNG ADENOCARCINOMA 
CHELSEA SYKORA 
ABSTRACT 
 Lung adenocarcinoma (LUAD) is a subtype of non small-cell lung cancer that has 
been characterized by late stage diagnosis and poor clinical outcomes. Recent advances 
in tumor genotyping and precision therapies have shifted the landscape of LUAD 
management, drastically improving outcomes for a large subset of patients. Specific 
tyrosine kinase inhibitors have been developed to target oncogenic aberrations harbored 
by different molecular subtypes of LUAD. Although many of these targeted therapies 
have proven to be more efficacious than traditional chemotherapy, the constant battle 
against acquired resistance has limited their success. This has warranted the development 
of second- and third-generation tyrosine kinase inhibitors, chronically directed at more 
and more specific targets. 
 This review focuses on the eight most frequent LUAD oncogenic drivers and the 
effectiveness of their associated targeted therapies. The goal of this thesis is to evaluate 
each molecular target as a candidate for precision medicine, identify targeted therapies 
which hold the most promise, and characterize the current state of LUAD precision 
therapy. By comparing progression free survival rates, safety profiles, and resistance data 
for each genetic aberration, it was concluded that epidermal growth factor receptor 
(EGFR) and ROS proto-oncogene 1 (ROS1) directed therapies hold the most promise for 
improving clinical outcomes for EGFR mutant-positive and ROS1 fusion-positive patient 
  vi 
populations. Though curative options will likely not be seen in the near future, the 
progress made by precision medicine is encouraging. By focusing further research on 
elucidating resistance mechanisms, identifying novel oncogenic drivers, and trialing 
combination therapies, patient outcomes can continue to improve. 
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INTRODUCTION 
 
 Lung cancer is the leading cause of cancer-related deaths, killing approximately 
1.6 million patients every year worldwide (Reck & Rabe, 2017; Zhou et al., 2011). In 
2016, it was estimated that there were over 200,000 new cases of lung cancer in the 
United States, with over 50% of cases being metastatic at initial diagnosis (Kumar, 
Abbas, Aster, & Perkins, 2018). As the majority of lung cancer cases are detected at a 
later stage, disease management has been an arduous task for clinical oncologists. Non-
small cell lung cancer (NSCLC) is a histological subtype that describes approximately 
85% of all lung cancer (Herbst, Morgensztern, & Boshoff, 2018). The two most common 
types of NSCLC are lung adenocarcinoma (LUAD) and lung squamous cell carcinoma 
(LUSC).  
Smoking tobacco has long been associated with lung cancer and is in fact the 
main cause for mutations leading to both types of NSCLC (Herbst et al., 2018). However, 
a substantial quarter of all United States lung cancer cases arise in “never smokers” with 
a majority of this population presenting with LUAD (Reck & Rabe, 2017; Rivera & 
Wakelee, 2016). Out of all the histological subtypes of lung cancer, LUAD is the least 
associated with tobacco and smoking cigarettes. Due to changes in smoking habits and 
cigarette composition over the last few decades, such as incorporation of filters and 
lowered tar and nicotine content, there has been a subsequent increase in the percentage 
of lung cancer patients with LUAD and decrease in the percentage of patients with LUSC 
(Gabrielson, 2006). Lung cancer in never-smokers is disproportionately represented in 
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younger patients (<40) and females, particularly of Asian descent. Though non-smoking-
related risk factors for lung cancer have been identified (viral, hormonal, environmental, 
genetic, previous lung disease), there is no known major cause of lung cancer (Sun, 
Schiller, & Gazdar, 2007).  
Due to the fairly recent discovery of several targetable oncogenic alterations, drug 
research and development for late stage LUAD has largely shifted from cytotoxic 
therapies to precision medicine, opening the door for more personalized treatment 
options. Despite these advancements, the great evolutionary capacity and intratumoral 
heterogeneity (ITH) of lung adenocarcinomas has unfortunately contributed to the 
diminished efficacy of many targeted drugs due to acquired resistance (Zhang et al., 
2014). ITH develops due to the many mutations which arise from massive tumor cell 
division and genetic instability. This leads to a large number of molecularly distinct sub-
populations of clones (Marusyk & Polyak, 2010). 
LUAD vs. LUSC 
LUAD and LUSC develop from different molecular pathways, arise in separate 
anatomical locations, and evolve from unique cells of origin (Kadara, Scheet, Wistuba, & 
Spira, 2016). Morphologic differences between the two subtypes are minimal and 
difficult to distinguish, so subclassification is typically determined using 
immunohistochemical (IHC) analysis of tissue specimens. LUAD-positive markers used 
in diagnostic IHC staining include mucicarmine, napsin A, CD7, and TTF-1. LUSC-
positive markers include p63, CK5/6, NTRK1/2, and HMWCK (Huang et al., 2016; 
Terry et al., 2010).  
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As tobacco use is more associated with LUSC than LUAD, cells of origin of 
LUSC are located in the larger airways which are exposed to cigarette smoke. Upon 
exposure, pluripotent basal cells in these anatomical regions promote metaplasia, 
dysplasia, and ultimately form the squamous precursor lesions of LUSC (Kadara et al., 
2016). These precursor lesions contain a common amplified oncogene, sex determining 
region Y-Box2 (SOX2), which goes on to be amplified in invasive LUSC. This oncogene 
is not at all involved in LUAD tumorigenesis (Bass et al., 2009; Yuan et al., 2010). 
Mutations in the phosphoinositide 3-kinase pathway and fibroblast growth factor 1 are 
also common genetic alterations in LUSC, occurring in over 30% and 25% of patients, 
respectively (Reck & Rabe, 2017). Although LUSC has many mutations which are 
implicated in its pathogenesis, they are typically not mutually exclusive, as they are in 
LUAD (Langer, Obasaju, et al., 2016).  
Managing LUSC has proven to be more challenging than managing LUAD, 
mainly due to the absence of clear oncogenic aberrations which drive its pathogenesis. 
Targeted therapies have thus had limited success in this subtype, placing the progress of 
LUSC precision medicine behind that of LUAD. Additional challenges include the older 
average age of LUSC patients, the greater frequency of comorbidities due to smoking, 
and the bleeding risks associated with its central anatomical location (Langer, Obasaju, et 
al., 2016). 
Pathogenesis of Lung Adenocarcinoma 
The pathogenesis of LUAD is still largely unknown. Most research points to a 
combination of multistep tumorigenesis and an accumulation of molecular abnormalities. 
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One of the hallmarks of cancer is sustained proliferative signaling (Hanahan & Weinberg, 
2011). In LUAD, this is primarily driven by genomic aberrations in certain oncogenes 
which lead to constitutively active tyrosine kinases. These aberrations can be in the form 
of overexpression due to increased copy number, mutations, or rearrangements with 
partner genes (Folch, Costa, Wright, & VanderLaan, 2015). These mutations are thus 
known as driver mutations, as they impart a selective growth advantage and support 
tumor progression (Vogelstein et al., 2013). Driver mutations appear at a higher 
frequency in LUAD genomes of never-smokers than smokers (Sun et al., 2007). Two of 
the most common somatic mutations found in LUAD are in the Kristen rat sarcoma 
(KRAS) and epidermal growth factor receptor (EGFR) genes. When these mutations are 
present, they are thought to influence tumor initiation since they are usually detected in 
the founder clones (Herbst et al., 2018). 
Mutations that arise endogenously, like ineffective DNA repair or spontaneous 
deamination, have been found to occur at different times in tumor development and have 
different clinical implications than mutations that arise exogenously. Transition mutations 
(A to G, C to T), formed endogenously, occur later in tumor evolution and promote 
metastasis. Transversion mutations (C to A), caused by smoking-associated exogenous 
processes, occur earlier in tumor development and do not promote metastasis (Shi et al., 
2016). 
Forms of lung cancer which are more often caused by tobacco-associated 
carcinogens, like LUSC, are centrally located and develop in the major bronchi. 
Conversely, lung cancers which are more often found in never smokers, like LUAD, are 
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peripherally located and arise in alveolar epithelial cells, bronchioles, and small bronchi 
which are less affected by smoking (Fig. 1) (Kadara et al., 2016; Sun et al., 2007). This 
locational difference indicates that both subtypes arise from different cells of origin and 
different molecular pathways (Kadara et al., 2016). It is now generally accepted that the 
cells of origin of LUAD are surfactant protein C expressing alveolar type II (AT2) cells, 
as both EGFR and KRAS signaling selectively activate their proliferation (Desai, 
Brownfield, & Krasnow, 2014). These cells, along with Clara cells and nonciliated small 
bronchioles, are part of the “terminal respiratory unit” (TRU) (Yatabe, 2010). The 
oncogenic potential of AT2 cells is explained by their role as alveolar stem cells and their 
regulation by EGFR and KRAS signaling. Activating mutations in either EGFR or KRAS 
can cause their transformation into rapidly growing tumors (Desai et al., 2014).  
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Figure 1: Peripheral compartment of the lung. The major histological subtypes of lung 
cancer develop in different anatomical compartments of the lung. LUAD arises 
predominantly from the peripheral airway compartment, as seen above, which is less 
affected by tobacco smoke. Note that AT2 cells are equivalent to type II alveolar cells 
diagrammed above. Modified from (College, 2013). 
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Multistep tumorigenesis involves a stepwise progression from preneoplastic 
lesions to the malignant phenotype (Kadara et al., 2016; Kadara & Wistuba, 2012). 
Atypical adenomatous hyperplasia (AAH) is the only known preneoplastic lesion 
involved in the sequential development of invasive LUAD (Kadara & Wistuba, 2012). 
AAHs are said to be involved in the transformation of TRU cells into preinvasive 
adenocarcinoma in situ (AIS) and then into invasive adenocarcinoma (Yatabe, Borczuk, 
& Powell, 2011). Further evidence into the role of AAH in the development of LUADs is 
their shared molecular alterations (Kitamura, Kameda, Ito, & Hayashi, 1999).  
In addition to sustained proliferative signaling driven by oncogenic aberrations, 
lung cancer is also promoted by the inactivation of tumor suppressor genes (TSGs). 
Tumor suppressors normally function as negative regulators of cell proliferation and cell 
survival. This regulation is lost when they are inactivated, which leads to enhanced tumor 
cell proliferative signaling, invasiveness, and metastasis (Cooper, 2000). TSG 
inactivation typically begins with a point mutation on one allele and is followed by a 
translocation, promoter methylation, or deletion in the other allele (Wistuba & Gazdar, 
2006). There are several TSGs that are involved in LUAD tumorigenesis, including TP53 
(46%), KEAP1 (17%), STK11 (17%), NF1 (11%), RB1 (4%), and CDKN2A (4%) 
(Cancer Genome Atlas Research Network, 2014). The TP53 gene is located on 17p13 
and is commonly mutated in all forms of lung cancer (Takahashi et al., 1989). Its normal 
protein product is activated in response to oncogenic stress or DNA damage. Upon 
activation, TP53 stimulates the expression of genes that trigger cell-cycle arrest and other 
cell division inhibitory processes. Mutations in TP53 thus lead to uncontrolled cell 
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division and contribute to tumor formation (A. C. Joerger & Fersht, 2016). Normal 
KEAP1 negatively regulates NRF2, a transcription factor that protects cells against 
xenobiotics and oxidative stress. Biallelic inactivation of KEAP1 eliminates this 
regulation, allowing NRF2 to stimulate expression of genes that protect tumor cells 
against chemotherapeutic agents (Singh et al., 2006). The STK11 gene encodes a 
serine/threonine kinase. Inactivation of this gene arises from mutations which result in 
either a truncated protein or a total loss of expression. STK11 inactivation is believed to 
influence the transition from premalignant severe dysplasia in AAH to malignant LUAD 
(Ghaffar et al., 2003). The NF1 gene encodes a protein called neurofibromin. This protein 
negatively regulates RAS signaling by converting active RAS-GTP to inactive RAS-
GDP. Mutations in NF1 thus lead to RAS activation and subsequent proliferative 
signaling. These mutations are known to often coexist with KRAS and TP53 mutations 
(Redig et al., 2016). The Rb1 gene encodes pRb, which inhibits the activity of the 
transcription factor, E2F (Chinnam & Goodrich, 2011). This inhibition prevents the 
expression of certain proteins involved in mitosis (Ishida et al., 2001). pRb can be 
inhibited by phosphorylation, which prevents it from binding to E2F and subsequently 
allows for the expression of mitotic proteins (Chinnam & Goodrich, 2011). 
Phosphorylation of pRb can be prevented by another common TSG, CDKN2A. The 
CDKN2A gene is located on 9p21 and encodes the p16INK4a protein. p16INK4a prevents the 
formation of the protein complex responsible for phosphorylating pRb. Thus, inactivation 
of p16INK4a can also lead to uncontrolled cell proliferation (Zhao, Choi, Lee, Bode, & 
Dong, 2016). Other TSGs that have been shown to influence the pathogenesis of some 
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subsets of LUAD include ATM, APC, and TSC1 (Kim et al., 2006; Ohgaki et al., 2004; 
Takamochi et al., 2001). Although TSGs play an important role in lung cancer 
development, they are not currently actionable or the target of any cancer therapies 
(Cancer Genome Atlas Research Network, 2014). 
 Epigenetic mechanisms, such as DNA methylation, histone deacetylation, and 
microRNA regulation, also play a role in LUAD pathogenesis (Castro et al., 2010). DNA 
methylation most commonly occurs on the 5’ cytosine carbon of CpG islands, which are 
often located in promoter regions. Methylation at these sites by DNA methyltransferases 
can lead to gene silencing (Liu et al., 2016). In LUAD, DNA methyltransferases are often 
overexpressed (Ansari, Shackelford, & El-Osta, 2016). DNA methylation in the promoter 
region of TSGs is one mechanism which leads to their inactivation (Liu et al., 2016). 
Noncoding miRNAs that regulate many proliferative and apoptotic pathways are also 
frequently downregulated in LUAD via methylation (Heller et al., 2012). As precursor 
lesions evolve from AAH to AIS to invasive adenocarcinoma, the frequency of DNA 
methylation gradually increases (Selamat et al., 2011). Histone deacetylation can have a 
similar effect to DNA methylation, as histone deacetylases make chromatin more 
compact and thus repress gene expression. Overexpression of histone deacetylases are 
common in lung cancer (Ansari et al., 2016). In fact, the greater the expression of histone 
deacetylases, the poorer the prognosis for patients with LUAD (Minamiya et al., 2010). 
Epigenetic changes are reversible, so hypomethylating agents and histone deacetylase 
inhibitors have been developed as therapeutics to counter cancer-promoting epigenetic 
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mechanisms. However, these drugs have not yet been specifically approved to treat lung 
cancer (Ansari et al., 2016). 
 Dysregulation of long non-coding RNAs (lncRNAs) (non-coding RNA longer 
than 200 nucleotides) has also been recently implicated in the development of NSCLC. 
Some of the more common lncRNAs that are associated with NSCLC are HOTAIR, 
HOTTIP, and MALAT1 (Zhan et al., 2017). High expression of HOTAIR in NSCLC is 
thought to lead to negative regulation of TP53 and activation of the Wnt signaling 
pathway (Deng, Zhou, Cui, Liu, & Ma, 2015; N. Zhai, Xia, Yin, Liu, & Gao, 2016). 
HOTTIP overexpression promotes proliferation and cell migration (Sang et al., 2016). 
MALAT1 overexpression promotes tumor growth and migration mainly through 
regulation of alternative splicing (Gutschner, Hämmerle, & Diederichs, 2013, p. 1; 
Schmidt et al., 2011). 
 Although not yet extensively described for LUAD, mutations in non-coding 
regulatory regions, such as promoters, enhancers, and UTRs, can also drive 
tumorigenesis. Mutations in both promoter and enhancer regions may alter binding sites 
for regulatory or transcription factors that can lead to stimulation or repression of gene 
expression (Piraino & Furney, 2016). Mutations in the UTR may induce or prevent 
binding of RNA binding proteins and miRNAs (Gan, Carrasco Pro, Sewell, & Fuxman 
Bass, 2018). Though they are relatively infrequent, mutations in the promoter region of 
telomerase reverse transcriptase (TERT) have been associated with NSCLC. Mutations in 
this region are commonly activating and result in greater telomerase expression. 
Preserving the length of telomeres strengthens tumor cell genomic stability, leading to 
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enhanced proliferation and reduced apoptosis. It has been found that the presence of these 
activating mutations are predictive of poor overall survival (Jung et al., 2017). 
Clinical Diagnosis and Treatment 
Due to the majority of lung cancer diagnosis happening at later stages, 70% are 
unable to be resected for further testing and categorization. Instead, tumor stage 
classification is initially established using positron-emission tomography with computed 
tomography (PET-CT) and magnetic resonance imaging (MRI) (Reck & Rabe, 2017). 
More advanced classification is then established using small biopsy and cytology 
specimens (Travis et al., 2012). Cytologic and tissue analysis definitively establishes the 
histological subtype based on morphologic features (Reck & Rabe, 2017). These 
specimens provide adequate tissue to perform molecular testing which establishes the 
presence of relevant driver mutations or translocations in the cancer genome. The 
technologies used for this broad molecular profiling include fluorescence in situ 
hybridization (FISH), reverse transcriptase-polymerase chain reaction (RT-PCR), and a 
variety of multiplex platforms, including next-generation sequencing (NGS). The latter 
provides an efficient method to test a wide variety of gene rearrangements and actionable 
mutations simultaneously, allowing the appropriate treatment to be promptly delivered to 
the patient (Ettinger et al., 2015). 
The five year overall survival rates for early stage lung cancer decrease from 80-
90% at stage IA to 56% at stage IIB (Goldstraw et al., 2016). For patients presenting with 
NSCLC at these early stages, surgical resection is the recommended treatment 
(Vansteenkiste et al., 2014). Though surgical resection significantly improves survival, 
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LUAD’s characteristic ITH increases the likelihood of post-surgical relapse. In other 
words, the larger the sub-clonal mutation fraction, the higher the chance of cancer 
recurrence (Consonni et al., 2015; Zhang et al., 2014). This also means that early stage 
LUAD has a higher likelihood of metastasizing if it has higher ITH (Herbst et al., 2018). 
In fact, up to 70% of post-surgical patients will develop at least one recurrent lesion 
(Consonni et al., 2015). Clinical trials are still ongoing to determine if there is any benefit 
in using targeted treatments as adjuvant therapy in patients with early stage lung cancer 
(Hirsch et al., 2017). Patients with inoperable stage III NSCLC are typically treated with 
concurrent chemotherapy and thoracic radiotherapy (Curran et al., 2011). 
Though surgical resection has been instrumental in treating early stage lung 
cancer, about 70% of lung cancers are already locally advanced or metastatic at initial 
diagnosis and need an alternative treatment approach (Molina, Yang, Cassivi, Schild, & 
Adjei, 2008). Local advancement and metastasis is in fact the major cause of death for 
patients with lung cancer. The five year survival rate for stage IV lung cancer patients is 
only 2-13% (Consonni et al., 2015). Patients who are diagnosed in this stage will proceed 
with a treatment plan based on whether or not they harbor actionable genomic 
aberrations. Platinum-based chemotherapy and anti-angiogenic therapy are typically 
given to those who do not fit a particular targeted therapy (Hirsch et al., 2017). 
Immunotherapy has also recently emerged as a key treatment option for patients with 
advanced NSCLC who do not harbor oncogenic drivers but have a high level of 
programmed death ligand 1 (PD-L1) expression (Reck et al., 2016). Patients who do fit a 
targeted therapy, however, have benefited from better progression-free survival (PFS), 
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objective response rate, overall survival, and quality of life over those who simply 
received chemotherapy (Hirsch et al., 2017; James C-H Yang et al., 2015). This has 
established the use of targeted therapy in the first-line setting for certain oncogene-
addicted lung cancers (Tan et al., 2016).  
Precision Medicine 
The major goal of precision medicine is to further stratify patients into 
subpopulations based on genetic, clinical, lifestyle, and biomarker information in order to 
better tailor therapy to the individual patient. It aims to categorize patients into groups 
who have similar predispositions to certain diseases and/or responsiveness to different 
therapeutic agents (König, Fuchs, Hansen, Mutius, & Kopp, 2017). Benefits of precision 
medicine include the ability to diminish negative side effects and maximize efficacy by 
selecting a treatment strategy which aligns appropriately to a patient’s genetic profile. 
This is in contrast to the conventional one-drug-fits-all approach, where drugs are given 
to large patient populations who fit into broad categories based on signs and symptoms. 
One of the limitations to this conventional approach is that individuals often have 
different responses to therapy; drugs may be effective in some patients but may be futile 
in other patients. This is largely due to gene variations within subpopulations of patients 
which effect their therapeutic response. Precision medicine cuts down on the guesswork, 
reducing trial-and-error prescribing by helping determine the efficacy of a drug before it 
is even administered. Other benefits of precision medicine include reduced healthcare 
costs, safer dosing, more focused drug development, and ultimately better patient care 
(Vogenberg, Isaacson Barash, & Pursel, 2010). 
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The Lung Cancer Mutation Consortium used multiplexed assays to test over 700 
lung adenocarcinomas for 10 oncogenic drivers and found that 64% of tumors had 
actionable drivers. The term “actionable” indicates that the effects of these oncogenic 
alterations can be negated by therapeutic agents (Mark G. Kris et al., 2014). Before the 
implementation of precision medicine into lung cancer management, treatment was 
determined mainly by the broad categorization of tumors as NSCLC or SCLC. Subtyping 
and molecular profiling of tumors are now routinely done in order to further stratify the 
cancer beyond these two classifications and identify optimal treatment options for the 
patient. It is understood that due to the vast ITH of LUAD, its molecular profile can 
evolve as the cancer progresses, so molecular tests may be done more than once 
throughout treatment to determine any necessary changes in treatment strategy (Politi & 
Herbst, 2015). Using multiplex tumor genotyping to identify these drivers has helped 
physicians choose appropriate targeted therapy and has also increased the lifespan of their 
patients (Mark G. Kris et al., 2014).  
 Driver mutations in LUAD are often present in genes that code for proteins in the 
receptor tyrosine kinase (RTK) mediated RAS-RAF-MEK-ERK signaling pathway (Fig. 
2) (Cancer Genome Atlas Research Network, 2014). This pathway is initiated by 
extracellular signals and subsequently leads to cell growth, differentiation, and survival. 
Oncogenic aberrations in upstream or downstream proteins within this pathway cause 
constitutive activation, leading to uncontrolled proliferation and tumor growth (Masliah-
Planchon, Garinet, & Pasmant, 2015).  
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Figure 2: RAS-RAF-MEK-ERK Pathway. Dimerization and autophosphorylation 
activates the RTK. Activated RTK recruits SOS, a guanine nucleotide exchange factor. 
SOS then activates RAS by exchanging GDP with GTP in its nucleotide binding site. 
Activated Ras-GTP activates RAF by inducing its autophosphorylation and dimerization. 
Activated RAF phosphorylates and activates the protein kinase, MEK. Activated MEK 
phosphorylates and activates the protein kinase, ERK. Phosphorylated ERK has many 
effectors in the nucleus and the cytosol, many of which lead to cell growth, proliferation, 
survival, and differentiation (Matallanas et al., 2011). Modified from (“Insulin im 
Gehirn,” 2018). 
 
In a Lung Cancer Mutation Consortium analysis, full tumor genotyping of over 
700 tumors revealed that 25% had the KRAS driver, 21% had the EGFR driver, 8% had 
ALK rearrangements, 3% the HER2 driver, and 2% had the BRAF driver (Fig. 3) (Mark 
G. Kris et al., 2014). MET amplification is seen in about 4% of LUAD (Sadiq & Salgia, 
2013). Another study found ROS1 translocations in 1-2% of patients with NSCLC 
(Bergethon et al., 2012). RET fusion products are also found in 1.7% of patients with 
LUAD (Wang et al., 2012). EGFR, ALK, HER2, MET, ROS1, and RET are all RTKs 
Survival 
Differentiation 
Proliferation 
Cell Growth 
Activated RTK 
 16 
(Arighi, Borrello, & Sariola, 2005; Facchinetti et al., 2017; Frampton et al., 2015; 
Iwahara et al., 1997; Lemmon, Schlessinger, & Ferguson, 2014; Julien Mazières et al., 
2013). KRAS is part of the RAS family, and BRAF is part of the RAF family of proteins 
(Brose et al., 2002; Marchetti et al., 2011). Important to note is that most of these 
mutations happen exclusively, which indicates that oncogene addiction is caused by 
single drivers (Dearden, Stevens, Wu, & Blowers, 2013). Despite the identification of 
several oncogenic drivers as possible targets for precision therapy, many patients with 
LUAD do not harbor alterations in the aforementioned common genes. This implies that 
there may be more oncogenic drivers and therapeutic targets to be identified (Shi et al., 
2016). Cancer in this category may also be promoted by other cancer-driving 
mechanisms, including epigenetic changes, lncRNA dysregulation, and non-coding 
genetic alterations, as described in the Pathogenesis of Lung Adenocarcinoma section 
above. 
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Figure 3: Known Oncogenic Drivers. Illustration of the frequency of eight major 
actionable oncogenic drivers that contribute to the pathogenesis of LUAD. These genetic 
aberrations activate the RTK mediated RAS-RAF-MEK-ERK pathway and are present in 
about 64% of lung adenocarcinomas (Cancer Genome Atlas Research Network, 2014; 
Mark G. Kris et al., 2014). 
 
Tyrosine kinase inhibitors (TKIs) are small molecules that are used as agents to 
target and block the function of RTKs and thus inhibit their downstream signaling 
network (Fig. 4). These small molecules have served as the major precision therapy to 
treat oncogene addicted LUAD (Folch et al., 2015). 
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Figure 4: Action of Tyrosine Kinase Inhibitors. TKIs bind and competitively inhibit 
the ATP-binding tyrosine kinase domain of specific RTKs. This blocks the constitutive 
activation of mutated receptors and stops downstream growth-promoting signaling 
pathways (Mirshafiey, Ghalamfarsa, Asghari, & Azizi, 2014). Taken from (UK, 2014). 
 
In spite of the great strides achieved by precision therapies, 5-year survival rates 
for patients with NSCLC are still under 20% (Zhou et al., 2011). This is largely due to 
inherent and acquired resistance to TKIs (Herbst et al., 2018). Acquired resistance 
develops predominantly due to the selection of resistant clones that were present prior to 
administration of the targeted therapy (Turke et al., 2010). When resistance has been 
established, repeat biopsy and evaluation of changes in the tumor genotype is 
recommended. Depending on the target, next steps could include trying second- and 
third-generation TKIs or switching to doublet chemotherapy. These next-generation 
therapies are designed to have more and more specific target effects, ultimately resulting 
in treatment regimens which continuously evolve (Hirsch et al., 2017). 
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Overview of Other Current Therapies 
- Surgical Resection and Chemotherapy 
Surgical resection is the best treatment for localized LUAD (X. Zhai et al., 2017). 
Research suggests that video-assisted thoracic surgery is the optimal technique for tumor 
resection and results in less complications, shorter hospitalizations, and better long-term 
outcomes compared with the former technique of open lobectomy (Cao, Manganas, Ang, 
Peeceeyen, & Yan, 2013). However, if treatment involves surgery alone, five year 
survival rates are 73% for stage IA and go down to only 25% for stage IIIA. When 
chemotherapy is added into the treatment regimen after surgical resection, significant 
improvement in this five year overall survival rate is noted (X. Zhai et al., 2017). When 
chemotherapy is administered after the primary surgical treatment to lower the chances of 
recurrence, it is being used as adjuvant therapy. A meta-analysis done by the Lung 
Adjuvant Cisplatin Evaluation found that when cisplatin was used as an adjuvant therapy 
postoperatively, patients experienced a 5.4% benefit of five year overall survival rate 
(Pignon et al., 2008). More recently, a retrospective study in patients with resected 
LUAD found that adjuvant platinum-based chemotherapy combined with pemetrexed 
results in longer disease-free survival (DFS) and lower clinical toxicity when compared 
with doublet regimens using other third-generation cytotoxic agents (ex. docetaxel, 
paclitaxel, gemcitabine) (X. Zhai et al., 2017). 
 In advanced stage NSCLC, platinum based chemotherapy (ex. cisplatin, 
carboplatin) plus pemetrexed has been considered a first-line therapy, having shown to be 
more effective than multiple other doublet regimens (Kreuter et al., 2013; Scagliotti et al., 
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2008). Cisplatin, or cisplatinum, works by crosslinking with purine bases and preventing 
DNA repair. This results in damaged DNA and consequent tumor cell apoptosis (Dasari 
& Tchounwou, 2014). Pemetrexed is an antifolate drug which inhibits three different 
enzymes involved in intracellular folate metabolism, resulting in antiproliferative activity 
(Fig. 5) (M. Joerger, Omlin, Cerny, & Früh, 2010). If an oncogenic driver is identified 
during first-line chemotherapy, 2015 National Comprehensive Cancer Network 
guidelines suggest that the chemotherapy may be interrupted and replaced by a targeted 
therapy (Ettinger et al., 2015). Comparative studies have shown that first-line targeted 
therapies confer better PFS than first-line chemotherapy by 3-8.5 months, according to 
the studies cited (Mitsudomi et al., 2010; Rosell et al., 2012; Sequist et al., 2013; Zhou et 
al., 2011). Depending on the target, a targeted therapy may also be added to the current 
chemotherapy (Ettinger et al., 2015). 
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Figure 5: Pemetrexed Mechanism. Pemetrexed inhibits three enzymes involved in 
folate metabolism: thymidylate synthase (TS), dihydrofolate reductase (DHFR), and 
glycinamide ribonucleotide formyltransferase (GARFT). Pemetrexed thus indirectly 
inhibits purine and pyrimidine synthesis. Pemetrexed mainly acts on TS, which catalyzes 
the rate-determining step in the synthesis of deoxythymidine triphosphate, an essential 
component of DNA (Li, Rivory, & Clarke, 2007). Modified from (Fdardel, 2011; Li et 
al., 2007). 
 
- Immunotherapy  
Typically, baseline immune surveillance in the body recognizes and eliminates 
most emerging cancer cells, thus preventing tumorigenesis. However, one of the major 
hallmarks of cancer is the ability to evade immune destruction, allowing it to overcome 
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the restraints of the immune system (Hanahan & Weinberg, 2011). Tumors are able to 
prevent detection by the immune system by adaptive expression of proteins known as 
immune checkpoints (Reck & Rabe, 2017). The immune checkpoint that is of highest 
interest as a target for LUAD management is programmed death-ligand 1 (PD-L1). PD-
L1 is highly expressed in tumors of 23-28% of patients with advanced NSCLC. “High 
expression” indicates that at least 50% of cancer cells express PD-L1 on their membranes 
(Reck et al., 2016). Programmed cell death protein 1 (PD-1) signaling delivers inhibitory 
signals within T cells and is stimulated by PD-L1 expressed by the tumor during 
tumorigenesis. This inhibitory signaling inactivates the tumor antigen-specific T cell, 
preventing tumor cell destruction by the immune system. Successful immune evasion 
allows for subsequent progressive tumor growth and metastasis (Iwai et al., 2002).  
Targeting and blocking PD-L1 or PD-1 with specific monoclonal antibodies, 
called immune checkpoint blockers (ICB), helps to reinstate anti-tumor T cell-mediated 
immunity (Fig. 6) (Topalian et al., 2012). Examples of anti-PD-1 antibodies are 
pembrolizumab and nivolumab (Borghaei et al., 2015; Garon et al., 2015). Examples of 
anti-PD-L1 antibodies are durvalumab, avelumab, and atezolizumab (Hirsch et al., 2017; 
Rittmeyer et al., 2017). Before the implementation of these immunotherapies for the 
management of LUAD, many patients who did not qualify for first-line targeted therapies 
had to resort to cytotoxic chemotherapy as a first-line treatment. The development of 
these ICBs has established a valuable treatment option for NSCLC patients who do not 
benefit from therapies based on genetic aberrations (Reck et al., 2016). 
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Figure 6: Action of Immune Checkpoint Blockers. A. PD-L1 expression by the tumor 
cell initiates PD-1 inhibitory signaling, suppressing T cell-mediated antitumor immunity. 
This allows cancer to go undetected by the immune system (Herbst et al., 2018). B. 
Monoclonal antibodies against PD-1 or PD-L1 prevent inhibitory signaling by blocking 
the PD-1/PD-L1 axis, allowing for T cell activation and subsequent cytotoxic activity 
towards the tumor cell (Iwai et al., 2002). 
 
For patients with advanced LUAD whose first-line chemotherapy has failed, 
immunotherapy is a viable next step. Nivolumab, pembrolizumab, and atezolizumab have 
all individually lead to longer overall survival by 3-4 months compared with docetaxel 
treatment, a chemotherapeutic agent. Side-effects and safety were also improved in 
patients treated with immunotherapy versus chemotherapy (Borghaei et al., 2015; Herbst 
et al., 2016; Rittmeyer et al., 2017). However, immunotherapy is not without adverse 
inflammatory events, so immunosuppressive medication is often incorporated into the 
regimen (Postow, Callahan, & Wolchok, 2015). In a follow-up study on the survival and 
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long-term safety of nivolumab in patients with previously-treated NSCLC, 2-year 
survival was almost double that of the overall population (S. N. Gettinger et al., 2015). 
Recently, patients with PD-L1-positive tumors have been able to receive 
immunotherapy in the front-line setting. In the KEYNOTE-024 phase 3 trial, previously 
untreated patients who had at least 50% PD-L1 expression were treated with 
pembrolizumab or platinum-based chemotherapy. Compared to the chemotherapy group, 
pembrolizumab resulted in better median PFS (10.3 months versus 6 months), superior 
overall survival at 6 months (80.2% versus 72.4%), greater response rate (44.8% versus 
27.8%), and fewer adverse events (73.4% versus 90%) (Reck et al., 2016). Another study 
compared Nivolumab to chemotherapy as a first-line treatment for patients with advanced 
NSCLC and a PD-L1 expression of at least 5%; however, there was no significant 
difference in PFS and overall survival (Carbone et al., 2017).  
Combining immunotherapy and chemotherapy has also been considered in the 
first-line setting, as they fortunately do not have an overlapping toxicity profile. In 
addition to its cytotoxic effects, chemotherapy also lessens the activity of T-regulatory 
cells, increases cross-presentation of tumor antigens, and stimulates cancer cell PD-L1 
expression. It makes sense that chemotherapy and immunotherapy can thus work together 
to improve their anti-tumor effects. One study compared chemotherapy plus 
pembrolizumab with chemotherapy alone in patients with advanced NSCLC. The 
chemotherapy plus pembrolizumab group experienced a 26% higher objective response 
than the chemotherapy only group. This study established combined chemotherapy and 
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immunotherapy as a potentially efficacious and tolerable first-line therapy for advanced 
LUAD (Langer, Gadgeel, et al., 2016). 
Though most ICB clinical trials have been done in patients with advanced 
NSCLC, research within the last 2 years has suggested a potential role for 
immunotherapy in the treatment of earlier stage, non-metastatic NSCLC. In the future, 
ICBs may be administered perioperatively or together with chemotherapy (Antonia et al., 
2017; Herbst et al., 2018). Even with such promising results from immunotherapy 
clinical trials, the majority of patients who benefit initially from monoclonal treatment 
ultimately acquire resistance (S. Gettinger et al., 2017; Zaretsky et al., 2016).  
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Specific Aims 
 
The use of genomic profiling and the development of targeted therapies in the 
past two decades have given rise to better personalized options for the management of 
LUAD. Improvement in patient outcomes has pushed precision medicine to the forefront 
of lung cancer research and into the first-line clinical setting. Still, acquired resistance to 
most of these drugs has limited their long-term success.  
The objective of this thesis is to comprehensively review the literature to 
characterize the current landscape of precision medicine in the context of LUAD 
management. This thesis investigates into the most frequent genetic aberrations that drive 
the development of LUAD and their associated targeted therapies in order to compare 
relative effectiveness to each other and to traditional cytotoxic chemotherapies. For 
comparative analysis, this thesis will focus mainly on rates of progression-free survival, 
adverse events, and propensity for acquired resistance. Based on these parameters, 
conclusions will be made on the current state of each molecular target as a candidate for 
precision medicine, the individual targeted therapies which hold the most potential, and 
the current state of LUAD precision medicine in general. 
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MAJOR GENETIC ALTERATIONS IN LUNG ADENOCARCINOMA AND 
ASSOCIATED TARGETED THERAPIES 
  
 Lung adenocarcinoma is highly heterogeneous and can be further classified into 
subtypes based on its genomic profile and the presence of specific tumorigenic 
alterations. Precision medicine takes advantage of this genetic subtyping by matching 
patient subpopulations with appropriate TKIs. This section will review eight of the major 
oncogenic drivers that lead to LUAD and the current or emerging drugs used to treat 
patients who harbor each of these actionable targets. 
EGFR Mutations 
 
The first and still most prevalent molecular target to be established for precision 
therapy of LUAD is EGFR. Activating mutations in EGFR are most commonly found in 
females, never smokers, and East Asian ethnicity (about 48% in East Asians) (Dearden et 
al., 2013; Mounawar et al., 2007). EGFR is one of four members of the human 
EGFR/ErbB family of RTKs. It has four extracellular domains, a transmembrane domain, 
a tyrosine kinase domain, and a carboxy-terminal tail that has five tyrosine 
autophosphorylation sites. When EGFR is activated by any of its seven known activating 
ligands, a signaling cascade results (Lemmon et al., 2014). The receptor dimerizes, 
transphosphorylates tyrosine residues via their tyrosine kinase domains, and goes on to 
recruit and activate several downstream effectors. This signaling cascade ultimately 
promotes proliferation and survival (Fig. 7) (Lynch et al., 2004). 
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Figure 7: EGFR Signaling. Schematic of ligand-activated, dimerized, and 
transphosphorylated EGFR initiating a signaling cascade involving numerous 
downstream effectors, ultimately leading to cell proliferation, angiogenesis, migration, 
adhesion, invasion, and apoptosis inhibition. Taken from (Eikuch, 2007). 
 
Oncogenic EGFR mutations in TKI-sensitive LUAD are found in exons 18 to 21, 
which code for the ATP-binding pocket of the tyrosine kinase domain. The most common 
mutations happen in exon 19 (in-frame deletions of amino acids 747-750) or in exon 21 
(missense mutation: L858R substitution). These mutations cause activation of EGFR 
signaling in the absence of a ligand (Lynch et al., 2004; Sharma, Bell, Settleman, & 
Haber, 2007). The patient subgroup whose tumors harbor these EGFR activating 
mutations have responded remarkably well to TKI therapy. In a meta-analysis including 
randomized trials of EGFR TKIs (gefitinib, erlotinib, and afatinib) versus first-line 
 29 
chemotherapy, TKI therapy decreased the risk of disease progression and death by 63% 
(C. K. Lee et al., 2015).  
Gefitinib is a first generation TKI, which functions as an EGFR-specific 
reversible competitive inhibitor (Herbst et al., 2018). Two studies that compared gefitinib 
to platinum-based chemotherapy as a first-line therapy showed superior PFS in the TKI 
group (10.8 months versus 5.4 months; 9.2 months versus 6.3 months). Both gefitinib and 
chemotherapy groups in all studies had acceptable, but varied kinds of adverse events 
(Maemondo et al., 2010; Mitsudomi et al., 2010). Erlotinib is another first generation 
EGFR-specific TKI. Studies that compared erlotinib to platinum-based chemotherapy as 
a first-line therapy also showed superior PFS in the TKI group (9.7 months versus 5.2 
months; 13.1 months versus 4.6 months). Importantly, chemotherapy was reported to 
cause worse treatment-related serious adverse events than erlotinib (14% versus 2%) 
(Rosell et al., 2012; Zhou et al., 2011). In a study that used the OPTIMAL and IPASS 
trials to compare the effectiveness of erlotinib versus gefitinib as a first-line treatment, 
they found a significant PFS difference (0.33) in favor of erlotinib (V. W. Y. Lee, 
Schwander, & Lee, 2014). 
Second generation EGFR TKIs include afatinib and dacomitinib, both of which 
are irreversible inhibitors of both EGFR and HER2 (Herbst et al., 2018). Interestingly, 
compared with chemotherapy, afatinib leads to longer overall survival in patients with 
exon 19 deletions, but has no effect in patients with exon 21 substitutions (James Chih-
Hsin Yang et al., 2015). When compared with first-line gefitinib, both afatinib and 
dacomitinib resulted in better PFS (11 months vs. 10.9 months and 14.7 months vs. 9.2 
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months, respectively) (Wu et al., 2017). Despite prolonged PFS and overall survival in 
second-generation EGFR TKIs over first-generation EGFR TKIs, second-generation 
EGFR TKIs have greater toxicity, making it difficult to establish which drug should be 
used in the first-line setting (Hirsch et al., 2017). 
Unfortunately, acquired resistance to first- and second-generation TKIs almost 
always happens after 9-13 months (Cortot & Jänne, 2014). The most common occurrence 
is the EGFR T790M mutation, which happens in about 50% of progressive tumors (Tan 
et al., 2016). This mutation results in a higher affinity for ATP, which diminishes the 
binding ability of first-generation reversible competitive TKIs. Second-generation 
inhibitors have also failed to inhibit EGFR T790M (Jänne et al., 2015). Osimertinib, also 
known as AZD9291 by AstraZeneca, is an example of a third-generation TKI that has 
been designed to overcome this resistance mechanism. By irreversibly and selectively 
inhibiting the T790M resistance mutation as well as the original mutation, this TKI can 
treat those who have experienced disease progression on first- and second-generation 
TKIs (Herbst et al., 2018; Jänne et al., 2015). In this population, osimertinib achieved a 
PFS of 9.6 months versus 2.8 months in patients without the T790M mutation (Jänne et 
al., 2015). Another study that compared osimertinib to first-generation EGFR TKIs in the 
first-line setting reported a superior PFS for osimertinib (18.9 months vs. 10.2 months). 
Osimertinib was also reported to have a similar safety profile and even lower rates of 
serious adverse events than erlotinib/gefitinib (Soria, Ohe, et al., 2017). These impressive 
results suggest that osimertinib could be a viable therapy in the first-line treatment of 
EGFR-positive LUAD (Herbst et al., 2018). However, resistance mechanisms to 
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osimertinib have also been described, including amplification of other RTKs, the 
Cys797Ser resistance mutation, and activation of MAPK signaling (Ercan et al., 2015; 
Hirsch et al., 2017; Thress et al., 2015). 
KRAS Mutations 
 KRAS mutations, which are more commonly associated with tobacco use, are the 
most common molecular change in NSCLC (M. G. Kris et al., 2011; Mounawar et al., 
2007). About 97% of KRAS mutations are found in exons 2 and 3, which leads to 
diminished RAS GTPase activity. This keeps RAS in its active state and prolongs the 
stimulation of downstream effectors (Brose et al., 2002; Karachaliou et al., 2013). 
However, many consider KRAS mutations to be unactionable, as efforts to target this 
phenotype have been largely unsuccessful (Herbst et al., 2018; Hirsch et al., 2017; Janne 
et al., 2016). Research has been done into using KRAS mutation status as a predictive 
marker for chemotherapy benefit, but the association was found to be insignificant (Tsao 
et al., 2005; Winton et al., 2009). KRAS has been established as a negative predictor of 
EGFR TKI benefit but is not used for predictive testing, as EGFR testing has proven to 
be a better indicator of response (Linardou et al., 2008; Roberts & Stinchcombe, 2013). 
There is some evidence that KRAS mutations may confer resistance to EGFR TKIs, 
though these mutations mostly do not overlap (Pao et al., 2005). 
ALK Translocations 
The second most prevalent molecular target to be established for precision 
therapy for LUAD is ALK. ALK is an RTK that is part of the insulin receptor 
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superfamily. ALK has an extracellular domain, a transmembrane region, and an 
intracellular kinase domain (Iwahara et al., 1997). When ALK is activated by its ligand, it 
dimerizes, autophosphorylates, and then recruits and activates several downstream 
effectors. Not much else is known about ALK function in humans (Lin, Riely, & Shaw, 
2017). The most common oncogenic alteration of ALK involves a translocation with the 
echinoderm microtubule-associated protein-like 4 (EML4) gene. EML4 and ALK are 
both on the p arm of chromosome 2 and are oriented opposite to each other (Soda et al., 
2007). The resultant fusion gene, EML4-ALK, produces a cytoplasmic chimeric protein 
that has a constitutively active tyrosine kinase domain (Fig. 8). This fusion is associated 
more with never smokers than smokers (Kwak et al., 2010). 
 
Figure 8: EML4-ALK Fusion. Schematic of one possible variant of the EML4-ALK 
fusion protein. EML4 contributes its N-terminal basic region, its HELP domain, and 
some of its WD-repeat region. ALK contributes its intracellular tyrosine kinase domain. 
The transmembrane domain of the original ALK RTK is not included in the final fusion 
protein (Soda et al., 2007). 
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Crizotinib is a first-generation ALK TKI that works as a selective and competitive 
inhibitor of the tyrosine kinase domains of both ALK and MET (Christensen et al., 2007; 
McDermott et al., 2008). When compared to chemotherapy in patients with previously 
treated advanced NSCLC, crizotinib resulted in a better PFS (7.7 months versus 3 
months) (Shaw et al., 2013). The superiority of crizotinib over chemotherapy was also 
evident in the first line setting, with a PFS of 10.9 months versus 7 months (Solomon et 
al., 2014). Patients in the crizotinib group of both of the above trials also reported better 
improvement in lung cancer symptoms and quality of life. 
 The two major second-generation ALK TKIs are alectinib and ceritinib (Reck & 
Rabe, 2017). Although first-line ceritinib results in a better PFS than chemotherapy in 
patients with ALK fusion-positive NSCLC (16.6 months versus 8.1 months), there are no 
trials comparing ceritinib to first-generation crizotinib in the first-line setting (Soria, Tan, 
et al., 2017). However, alectinib has been compared to crizotinib as a first-line treatment 
in both the J-ALEX and ALEX clinical trials, which showed superior efficacy and less 
toxicity in the alectinib groups. Median PFS of alectinib was not reached in either study; 
however, 1 year PFS in ALEX was 68.4% with alectinib versus 48.7% with crizotinib. 
Adverse events resulting in dose interruptions and treatment discontinuation were less in 
the alectinib groups of both studies as well. These findings suggest that alectinib may be 
a viable first-line therapy for ALK-positive LUAD (Hida et al., 2017; Peters et al., 2017).  
 Success of first-generation ALK TKIs has been hindered by their susceptibility to 
acquired resistance. The majority of LUAD treated by crizotinib will progress within a 
year, almost all of which will involve the central nervous system (Costa et al., 2015; 
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Solomon et al., 2014). Many different kinds of resistance mechanisms have been 
described, including secondary mutations in ALK, ALK copy number alterations, and 
several bypass tracks (activation of other proliferative signaling pathways in order to 
bypass ALK signaling) (Dagogo-Jack & Shaw, 2016). Second-generation ALK TKIs 
have been reported to achieve a median PFS of 7 months in ALK-positive patients who 
had developed resistance to crizotinib (Shaw, Kim, et al., 2014). Even with this 
temporary solution, patients invariably develop resistance to second-generation TKIs as 
well. Many of the patients who experience disease progression on first- and second-
generation ALK TKIs have acquired the solvent front mutation, ALK G1202R, which 
sterically interferes with TKI binding (Shaw et al., 2017). Lorlatinib is a third-generation 
ALK TKI that targets resistance mechanisms such as ALK G1202R and is brain-
penetrant (Johnson et al., 2014). PFS for ALK-positive patients who received at least two 
previous TKIs was 9.2 months, and it was 13.5 months for patients treated with one 
previous TKI (Shaw et al., 2017). Clinical trials are ongoing to determine the efficacy of 
lorlatinib as a first-line treatment for patients with ALK-positive NSCLC (Shaw et al., 
2017).  
ROS1 Translocations 
 ROS1 is another RTK that is part of the insulin receptor superfamily (Facchinetti 
et al., 2017). ROS1-positive NSCLC is relatively uncommon (1-2% of NSCLC); 
however, in the patient populations that do not harbor EGFR or ALK aberrations, the 
prevalence in never smokers rises to 5%. ROS1 is another RTK which forms an aberrant 
fusion protein that results in its constitutive activation (Lim et al., 2017). ROS1 has 
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several different fusion partners, but the most common one is CD74 (Facchinetti et al., 
2017). The ROS1 gene is located on chromosome 6q22, and the aberrant translocation 
fuses exon 6 of CD74 to exon 34 of ROS1 (Fig. 9) (Awad et al., 2013; Bergethon et al., 
2012). No matter what the fusion partner is, ROS1 maintains its kinase domain (Zou et 
al., 2015). 
 
 
Figure 9: CD74-ROS1 Fusion. Schematic of the major variant of the CD74-ROS1 
fusion protein. Exon 6 of CD74 is fused to exon 34 of ROS1. In the plasma membrane, 
the N-terminus of CD74 begins intracellularly. The fusion protein enters the extracellular 
compartment via the CD74 transmembrane domain and then returns back to the 
intracellular compartment via the ROS1 transmembrane domain. The intracellular C-
terminal portion contains the ROS1 tyrosine kinase domain (Awad et al., 2013). 
 
Due to the high homology of ROS1 and ALK, especially in the kinase domain, 
the TKIs that target ALK-positive NSCLC are also effective in treating ROS1-positive 
NSCLC (Chin, Soo, Soong, & Ou, 2012; Lim et al., 2017). In fact, there is 77% amino 
acid homology between the ATP-binding sites of ROS1 and ALK kinase domains (Shaw, 
Ou, et al., 2014). However, survival metrics are different between the two targets when 
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treated with the same drugs. First-generation crizotinib is currently the single approved 
TKI for the treatment of ROS1-positive NSCLC (Pakkala & Ramalingam, 2018). A study 
which tested crizotinib in advanced ROS1-positive patients, most of whom had received 
at least one previous round of chemotherapy, reported a median PFS of 19.2 months. Half 
of these patients did not even reach progression at the completion of this trial. This study 
also reported a similar safety profile to crizotinib use in ALK-positive patients (Shaw, 
Ou, et al., 2014). Another study tested second-generation ceritinib in ROS1-positive 
patients (pre-treated with chemotherapy) and reported a median PFS of 9.3 months for all 
patients and 19.3 months in patients who had never received crizotinib (Lim et al., 2017). 
The same lorlatinib study cited in the ALK translocation section above also assessed 
lorlatinib effectiveness in ROS1-positive patients. They reported a median PFS of 7 
months for ROS-positive patients, half of whom had previously received crizotinib (Shaw 
et al., 2017). Direct comparisons of ROS1/ALK TKIs or trials in the first-line setting for 
ROS1-positive patients have not yet been done. 
 Expectedly, mechanisms of acquired resistance to crizotinib have been identified 
for ROS1 translocations. The majority of resistance comes from secondary mutations, the 
most common one being G2032R, located in the ROS1 kinase domain. This causes steric 
interference with the TKI (Awad et al., 2013; Hirsch et al., 2017). Another mechanism of 
resistance that has been observed is a switch from ROS1 signaling to EGFR signaling for 
growth and survival. It has been suggested that possible co-inhibition of ROS1 and EGFR 
may be effective in overcoming this mechanism of resistance (Davies et al., 2013). 
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BRAF Mutations 
 BRAF is a nonreceptor serine/threonine kinase that is downstream of RAS in the 
RAS-RAF-MEK-ERK pathway. Its kinase domain shares structural similarity to RTK 
kinase domains. About half of BRAF-positive NSCLC harbors the actionable mutation, 
T1799A, a transversion in exon 15. This leads to the amino acid substitution, V600E, 
which is highly associated with females and with negative prognosis. Other non-V600E 
mutations have been identified and are found solely in the smoker patient population 
(Marchetti et al., 2011). However, these mutations have been suggested to be resistant to 
BRAF TKIs (Cardarella et al., 2013). 
 Vemurafenib is a selective inhibitor of the BRAF V600E kinase domain, 
originally developed to treat metastatic melanoma with this mutation. A basket study, 
which tests the effects of one drug on a variety of cancers that share a genetic aberration, 
assessed the effectiveness of vemurafenib in various nonmelanoma cancers that have the 
BRAF V600E mutation. The PFS in NSCLC patients was 7.3 months. 90% of these 
patients had been previously treated with platinum-based chemotherapy. They reported 
the response rate for vemurafenib was superior to the response rate for standard second-
line docetaxel. Sample sizes in this study were too small within the individual cancer 
groups to determine a definitive safety profile (Hyman et al., 2015).  
Dabrafenib is another selective inhibitor of the BRAF V600E kinase domain. A 
study was done to assess the effectiveness of dabrafenib in mostly pretreated patients 
with advanced BRAF V600E positive NSCLC. In this patient population, the median PFS 
was reported to be 5.5 months. This PFS is longer than the PFS from docetaxel and 
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EGFR TKI treatment in patients with EGFR and ALK wild-type NSCLC (2 months with 
docetaxel and 3 months with EGFR TKI). Serious adverse events with dabrafenib were 
comparable to those with docetaxel and EGFR TKI (Planchard, Kim, et al., 2016). In 
another study, dabrafenib was administered with trametinib to patients with previously 
treated advanced BRAF V600E positive NSCLC. Trametinib is a MEK inhibitor and was 
added with the hope that duel RAS-RAF-MEK-ERK pathway inhibition may enhance 
outcomes, as this improvement was seen in BRAF V600 positive melanoma. Median PFS 
in this study was reported to be 9.7 months, and the safety profile was similar to that in 
BRAF V600 positive melanoma patients (Planchard, Besse, et al., 2016). This PFS is not 
only significantly longer than the PFS reported for dabrafenib and vemurafenib 
monotherapy, but also for second-line chemotherapy (3.1 months) (Barlesi et al., 2016). 
Direct comparisons of vemurafenib and dabrafenib to each other or to chemotherapy as 
first-line therapies for BRAF mutant-positive patients have not yet been done. The rarity 
of the BRAF V600E mutation in NSCLC limits the ability to do large randomized trails 
(Planchard, Kim, et al., 2016). 
Resistance mechanisms have not yet been elucidated for BRAF-positive NSCLC. 
However, they are likely similar to the acquired resistance (due to reactivation of 
pathway signaling) that has been reported in BRAF V600 positive melanoma (Planchard, 
Besse, et al., 2016). 
MET Exon 14 Mutations 
 The MET gene encodes the hepatocyte growth factor (HGF) receptor, which is a 
RTK that is involved in cell growth regulation. Stimulation of normal MET leads to 
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motility, morphogenesis, and mitogenesis. In NSCLC, mutated MET leads to cancer cell 
proliferation, angiogenesis, and invasion. The oncogenic activity of MET results from 
several different mutations that cause the splicing mechanism to skip exon 14. Exon 14 
(METex14) contains an amino acid, Y1003, which is important for the coding of a 
specific part of the RTK that is necessary for the recruitment of CBL. CBL is a ubiquitin 
ligase that targets the MET protein for ubiquitination and degradation. Missing exon 14 
thus results in a more stable MET protein that can sustain signaling activity when 
activated by its ligand (Fig. 10) (Frampton et al., 2015).  
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Figure 10: MET Stabilization from exon 14 skipping. METex14 encodes a portion of 
the juxtamembrane domain that has the amino acid, Y1003. The left panel shows a 
normal MET RTK protein product that can be bound by CBL at the Y1003 binding site, 
triggering ubiquitination and degradation of the receptor. Mutations in the splice sites 
surrounding MET exon 14 result in oncogenic exon 14 skipping and the exclusion of the 
justamembrane domain from the final protein product. CBL is unable to bind due to the 
absence of Y1003, and MET is stabilized. Prolonged signaling leads to tumor cell 
proliferation, angiogenesis, and invasive growth (A. Drilon, Cappuzzo, Ou, & Camidge, 
2017; Frampton et al., 2015). 
 
  
Patients with METex14-mutant LUAD tend to be older than patients with other 
common genetic aberrations (median age is 72.5 years). They are also more likely to be 
never smokers than KRAS-positive patients, but less likely than EGFR-positive patients 
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(Awad et al., 2016, p. 14). Many patients with METex14 mutations also have concurrent 
MET amplification and MET overexpression, which have been reported to possibly 
increase the response to MET inhibitors (Frampton et al., 2015).  
The studies that have tested MET-directed targeted therapy for METex14 mutant-
positive LUAD are limited to small case reports (1-4 patients). These reports have shown 
very favorable responses and tolerable adverse event profiles with crizotinib, capmatinib, 
and cabozantinib in previously treated METex14 mutant-positive patients. Current 
research calls for further prospective clinic trials to fully characterize the efficacy of these 
TKIs in the treatment of this LUAD subtype (Awad et al., 2016; Dietrich, Yan, & 
Schiller, 2015; A. E. Drilon et al., 2016; Paik et al., 2015; Waqar, Cottrell, & 
Morgensztern, 2015). Due to the lack of clinical trials, PFS metrics do not exist and 
resistance mechanisms have not yet been elucidated. 
HER2 Mutations 
 HER2-mutation positive LUAD affects a similar patent population to EGFR 
positive LUAD: never smokers and females. The HER2 protein is part of the erbB RTK 
family. Upon activation by its ligand, HER2 dimerizes and initiates signaling via PI3K 
and RAS-RAF-MEK-ERK pathways. This signaling promotes tumor cell proliferation 
(Julien Mazières et al., 2013). One oncogenic alteration that leads to LUAD is an in-
frame insertion in exon 20. This leads to a narrowed ATP binding cleft, which enhances 
the enzymatic activity of its tyrosine kinase (Perera et al., 2009). HER2 gene 
amplification and overexpression are also oncogenic drivers of NSCLC (Julien Mazières 
et al., 2013). 
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 Clinical research involving HER2-targeted therapies is lacking. However, one 
retrospective study evaluated the efficacy of multiple HER2 targeted drugs in pretreated 
patients with HER2-positive NSCLC. Targeted drugs included were lapatinib, afatinib, 
and trastuzumab; however, lapatinib apparently was not associated with any benefit. The 
median PFS for patients receiving these TKIs was 5.1 months, which led investigators to 
be optimistic about HER2 mutations being predictive of HER2 targeted therapy response. 
However, this is currently just speculation (Julien Mazières et al., 2013). Previous studies 
of combined chemotherapy and trastuzumab have not shown any benefit (Gatzemeier et 
al., 2004). Another study that evaluated afatinib in three previously-treated patients with 
HER2 mutation-positive LUAD reported a response in all three patients. Two of these 
patients had undergone other unsuccessful trials of EGFR and HER2 targeted therapies 
(De Grève et al., 2012). A more recent retrospective study evaluated the use of 
chemotherapy and varied HER2 targeted drugs in previously treated patients with HER2 
mutation-positive LUAD. Afatinib, trastuzumab, lapatinib, neratinib, and T-DM1 were 
the targeted drugs included in the study. The HER2 targeted inhibitors were typically 
administered alone, while trastuzumab was typically administered concurrently with 
chemotherapy. Chemotherapy with no targeted therapy used as first-line and second-line 
therapy resulted in PFS rates of 6 months and 4.3 months, respectively. PFS for patients 
receiving trastuzumab with chemotherapy was 5.1 months. PFS for patients receiving 
afatinib was 3.9 months. PFS rates for neratinib were not evaluated, and the patients on 
lapatinib progressed by the first assessment (J. Mazières et al., 2016). The current 
literature have not extensively reported on any specific HER2 resistance mechanisms. 
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RET Translocations 
 The RET protein is a RTK that is made up of an intracellular tyrosine kinase 
domain, a transmembrane domain, and an extracellular domain. The extracellular region 
is characteristically rich in cysteines and contains four cadherin-like repeats (Arighi et al., 
2005). The most common actionable oncogenic RET aberration associated with LUAD is 
an in-frame fusion with the kinesin family 5B (KIF5B) gene (Gautschi et al., 2017; 
Kohno et al., 2012). The RET gene is located on 10q11.2, and the KIF5B gene is located 
on 10p11.2. The fusion of these two chromosome 10 genes occurs due to an inversion in 
the area of the centromere. Every variant of the KIF5B-RET fusion protein preserves 
both the tyrosine kinase domain of RET and the coiled-coil domain on KIF5B (allows for 
ligand-independent homodimerization) (Fig. 11). This leads to constitutive activation and 
oncogenic activity (Kohno et al., 2012). 
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Figure 11: KIF5B-RET Fusion. Schematic of one possible variant of the KIF5B-RET 
fusion protein. KIF5B contributes its N-terminal kinesin motor domain and a portion of 
its coiled-coil domain. RET contributes its intracellular tyrosine kinase domain. The 
transmembrane domain of the original RET RTK is not included in the final fusion 
protein (Ferrara, Auger, Auclin, & Besse, 2018; Kohno et al., 2012). 
 
Research revolving around the potential of RET TKIs is fairly new and thus 
limited. A prospective phase 2 trial was done to assess the efficacy of cabozantinib in 
RET fusion-positive LUAD, and the PFS was reported to be 5.5 months (A. Drilon et al., 
2016). A similar study was done to assess the efficacy of vandetanib (originally 
developed for the treatment of thyroid cancer), which resulted in a PFS of 4.7 months and 
a tolerable safety profile (Commander, Whiteside, & Perry, 2011; Yoh et al., 2017). More 
recently, a retrospective study on previously treated patients with stage III and IV LUAD 
assessed the effectiveness of a variety of RET TKIs. The median PFS rates for individual 
inhibitors were 3.6 months with cabozantinib, 2.9 months with vandetanib, and 2.2 
months with sunitinib. This was compared to survival rates in RET fusion-positive 
 45 
patients who received first-line chemotherapy (median PFS of 7.8 months) (Gautschi et 
al., 2017). Like MET and HER2, clinical trials and discussion of potential resistance 
mechanisms are lacking.  
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DISCUSSION 
 
 Precision medicine has drastically changed the landscape of LUAD management 
by introducing TKI therapy into first and second-line settings. This has resulted in a 
better and wider array of treatment options for many who suffer from this disease. A 
thorough review of the literature surrounding this topic reveals the positive impact 
targeted therapies have made on survival rates and treatment tolerability. Eight of the 
most frequent LUAD-driving genetic aberrations were examined, and survival rates and 
safety profiles were outlined for each of their associated TKIs. Through this review, it is 
evident that the strength of clinical data is not equal for each of the molecular targets and 
that the use of TKI treatment has been more successful in some subtypes than others. 
This section will discuss the current state of targeted therapy for each oncogenic driver 
based on the review of literature presented in this thesis. 
 Oncogenic EGFR has been the most extensively researched molecular target in 
the development of precision therapies for LUAD. This is likely due to the high 
frequency of EGFR mutations in the LUAD patient population, which would make drug 
discovery efforts a high priority and highly funded. It was also the first of the eight 
mentioned targets to be identified as a driver that confers sensitivity to TKIs, so there has 
been more time for drug development and clinical trials (Lynch et al., 2004; Paez et al., 
2004). This has allowed the first-line treatment of EGFR mutant-positive LUAD to 
transition completely to TKI therapy, which is not the case for some other molecular 
targets (Tan et al., 2016).  
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 Out of the five major TKIs studied to treat EGFR mutant-positive LUAD, first-
line use of the third-generation EGFR TKI, osimertinib, resulted in a PFS almost nine 
months longer than current approved first-line TKIs as well as a superior safety profile 
(Soria, Ohe, et al., 2017). This was due to its activity against both the original mutation as 
well as the most common resistance mutation, EGFR T790M. However, the great ITH 
and adaptability of LUAD still poses a threat to its success, as resistance mechanisms 
have already begun to be elucidated against this drug (Ercan et al., 2015; Thress et al., 
2015). Solutions may be found in TKIs that have more and more specific target effects, 
which may prevent resistance or prolong the progression free survival period. There has 
also been research on combination strategies involving EGFR TKIs plus immunotherapy 
or chemotherapy, which may combat the onset of resistance (Stahel et al., 2015; Wu et 
al., 2013). 
 Research surrounding the use of mutated KRAS as a molecular target for TKIs or 
as a predictive marker for chemotherapy or EGFR TKI benefit was found to be largely 
disappointing. Despite KRAS being the most common oncogenic driver in patients with 
LUAD, it has had the least TKI response of all eight major targets (Mark G. Kris et al., 
2014). It is likely that KRAS mutant-positive LUAD patients will continue to rely heavily 
on chemotherapy and will probably benefit from more routine use of immunotherapies in 
the future. 
 ALK fusion is the next most frequent actionable genetic aberration in the LUAD 
patient population after EGFR and has also been the subject of extensive research (Mark 
G. Kris et al., 2014). Results of second-generation ALK TKI trials have been 
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encouraging, with ceritinib doubling the PFS of first-line chemotherapy and alectinib 
raising the 12 month PFS by 20% when compared to current first-line crizotinib. Safety 
profiles were also superior (Peters et al., 2017; Soria, Tan, et al., 2017). Third-generation 
lorlatinib, which targets both original and resistant mutations, seems to have great 
potential to take over first-line ALK fusion-directed therapy as osimertinib did in EGFR-
directed therapy; however, this has yet to be confirmed by clinical trial (Shaw et al., 
2017). It can be reasonably assumed that acquired resistance against lorlatinib will likely 
be observed with time. 
The high homology between ALK and ROS1 has accelerated the progress of 
ROS1 fusion-directed therapy, as it responds to the same TKIs as ALK (Lim et al., 2017). 
Interestingly, ROS1 seems to respond significantly better than ALK to crizotinib in 
previously treated patients (PFS of 19.2 months versus 7.7 months), although the safety 
profiles were similar (Shaw et al., 2013; Shaw, Ou, et al., 2014). This may translate to a 
better prognosis for advanced ROS1 fusion-positive patients. However, this comparison 
may also be irrelevant in the near future, as first-line TKI therapy for ALK fusion-
positive patients may transition to alectinib or lorlatinib, given their longer PFS rates 
(Peters et al., 2017; Shaw et al., 2017). ROS1 trials have not yet explored the use of 
second-generation TKIs in the first-line setting, so it is difficult to make any claims on 
the superiority of those TKIs in either ROS1 or ALK fusion-positive patients. Shaw et. al. 
examined lorlatinib in both ALK and ROS1 fusion-positive patients, which conversely 
showed a better response in patients with ALK fusion-positive NSCLC (Shaw et al., 
2017). This may imply a better prognosis for patients with acquired resistance to 
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crizotinib due to ALK G1202R than ROS1 G2032R resistance mechanisms. ROS1 
research is newer than ALK research in the realm of LUAD precision medicine, so there 
is naturally less clinical evidence supporting ROS1 TKI therapy. This may also be due to 
the lower frequency of the ROS1 fusion, likely causing it to be a lower priority (Mark G. 
Kris et al., 2014). 
Treating BRAF-positive patients poses an interesting challenge, as only half of 
the cases harbor the actionable V600E substitution (the other half is unactionable) 
(Cardarella et al., 2013). So far, the most promising strategy to combat BRAF-positive 
LUAD is a combination of dabrafenib and trametinib (BRAF and MEK inhibitors, 
respectively), which lengthened the PFS to 9.7 months from 2 months with chemotherapy 
and had an acceptable safety profile (Planchard, Besse, et al., 2016; Planchard, Kim, et 
al., 2016). This PFS rate is comparable to EGFR TKI PFS rates, which is encouraging 
given the progress made by EGFR-directed therapy. However, due to the rarity of this 
LUAD subtype, large clinical trials for BRAF-directed drug candidates are unlikely to 
happen (Planchard, Kim, et al., 2016). Thus, results of smaller trials, like the BRAF TKI 
trials cited above, may be enough clinical evidence to implement routine precision 
therapy into the first-line treatment regimen in the near future (Planchard, Besse, et al., 
2016). The success of this combination TKI therapy may also predict success of similar 
combination TKI therapies for other molecular targets. 
Research on METex14, HER2, and RET directed therapies is very limited, which 
makes it difficult to predict the future success of precision medicine for these molecular 
targets with any certainty. Three different TKIs have shown favorable responses and 
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tolerable safety profiles in case reports of patients with METex14 mutant-positive 
LUAD; however, PFS rates were not evaluated in such small cohorts (Awad et al., 2016; 
Dietrich et al., 2015; A. E. Drilon et al., 2016; Paik et al., 2015; Waqar et al., 2015). 
There may be an added benefit to implementing TKI therapy into the treatment regimen 
for METex14 mutant-positive LUAD, as it more commonly presents in older patients 
who are often unable to tolerate normal doses of traditional chemotherapy (Awad et al., 
2016). There is evidence of response to HER2-directed therapies; however, the PFS rates 
of HER2 TKIs in all of the studies discussed in this thesis were about the same or less 
than that of chemotherapy (De Grève et al., 2012; Gatzemeier et al., 2004; J. Mazières et 
al., 2016; Julien Mazières et al., 2013). Mazières et al. were unable to make conclusions 
on the superiority of any of the five drugs they examined in their retrospective study. 
Research suggests keeping chemotherapy as the standard of treatment, as it is unclear 
whether there is enough benefit from HER2 TKIs to establish their role in the 
management of HER2-positive LUAD. On the other hand, HER2 TKIs may be of value 
in patients who are unable to receive chemotherapy (J. Mazières et al., 2016). There is 
also evidence of response to RET-directed therapies; however, similar to HER2, the PFS 
rates were unimpressive (A. Drilon et al., 2016; Gautschi et al., 2017; Yoh et al., 2017). 
Gautschi et al. explained that this may be due to a higher toxic profile which limits the 
tolerable dose. This group suggests that RET TKIs may have a role as second-line 
treatments for the management of RET-positive LUAD. 
Considering the relatively weak clinical research that has been done on BRAF, 
MET, HER2, and RET, resistance mechanisms for these targets are expected to occur but 
 51 
have yet to be identified. Also bearing in mind the relative newness of the research and 
lower frequencies of these targets, it will likely be a challenge for research in these 
LUAD subtypes to catch up with the substantial progress that has been made for EGFR, 
ALK, and ROS1 subtypes already.  
Out of all the survival rates examined in this thesis, osimertinib targeted against 
EGFR and crizotinib and ceritinib targeted against ROS1 all had similar high PFS rates 
(18.9 months, 19.2 months, and 19.3 months, respectively) (Lim et al., 2017; Shaw, Ou, 
et al., 2014; Soria, Ohe, et al., 2017). These three TKIs resulted in the most impressive 
progression free survival rates of all drugs examined in this thesis. It should be noted, 
however, that many of the comparisons made in this discussion are cross-trial, which of 
course are not ideal and do not stand up to controlled, direct comparisons. This thesis also 
considers both previously treated and previously untreated patient populations, which 
adds another limitation to this comparison. 
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CONCLUSIONS AND FUTURE DIRECTIONS 
 
Lung cancer has a long history of poor prognoses and poor outcomes given its 
typical late-stage diagnosis and inadequate treatment options. Smoking cessation 
initiatives and altered cigarette content significantly transformed the frequency of lung 
cancer diagnosis for the better. However, the adenocarcinoma histological subtype 
develops largely in non-smokers, which has maintained the tremendously high incidence 
of this disease and has kept it at the forefront of lung cancer research (Gabrielson, 2006). 
With the advancement of multiplex sequencing techniques and the implementation of 
routine tumor genotyping within the last two decades, precision medicine has emerged as 
a viable and promising treatment strategy for several cancers, including lung 
adenocarcinoma. Despite this progress, acquired resistance to targeted therapies has 
hindered their success, and disease progression is more often than not inevitable. 
It is clear that osimertinib, crizotinib, and ceritinib directed against EGFR- and 
ROS1-positive LUAD have had the most success in prolonging progression free survival 
and maintaining acceptable or superior safety profiles. The future of precision therapies 
against these two targets is currently the most promising; however, EGFR research will 
likely progress faster than ROS1, as it impacts a significantly larger patient population. 
The success of ROS1-directed therapies will only benefit a small subset of the LUAD 
patient population. Although ALK-directed therapy has room to improve, its third-
generation TKIs will likely serve as an excellent next step for first-generation TKI-
resistant patients. There is reason to be relatively optimistic about MET-directed therapy, 
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but more clinical trials must be completed and resistance observed to determine this with 
greater confidence. Studies on BRAF-directed therapies have been encouraging and may 
open the door for other molecular targets to be trialed with dual TKIs. Currently, 
response to HER2 and RET directed therapies has been disappointing and will probably 
not take over as the standard first-line treatment if progression free survival rates remain 
unimpressive compared to traditional chemotherapy. However, screening for these 
aberrations should still be considered, so further clinical research can attempt to improve 
this situation (Gautschi et al., 2017; J. Mazières et al., 2016). Since KRAS has proven to 
be largely unactionable, resources may be better spent on other treatment strategies for 
this subpopulation. Due to the great success of targeted therapies against five of the eight 
genetic aberrations, it is important for clinicians to continue screening tumors in order to 
quickly implement the most efficacious therapy after diagnosis (Ettinger et al., 2015). 
Once the patient has experienced disease progression on their treatment regimen, it is also 
important to perform repeated screenings so therapy can be altered according to the 
resistance mutations or other actionable markers found (Novello et al., 2016).  
The screenings used to identify resistant clonal populations are typically carried 
out through repeated tumor biopsies. These procedures are risky and not always practical 
or ethical, especially in late stage cancer (Oxnard et al., 2016; Schwarzenbach, Hoon, & 
Pantel, 2011). Tumor biopsies are also not likely to be representative of the whole 
resistant cancer genome due to the significant ITH and clonal evolution of LUAD, 
potentially leaving important aberrations overlooked (Heitzer, Ulz, & Geigl, 2015; 
Oxnard et al., 2016). Circulating tumor DNA (ctDNA) and circulating tumor cell (CTC) 
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genotyping via blood draws, or “liquid biopsies”, has recently been identified as a better, 
less invasive alternative to tumor biopsies. CTCs are tumor cells that have been released 
into the circulation. ctDNA are DNA fragments that have been released from tumor cells 
or CTCs into the circulation and are representative of the entire tumor genome (Akca et 
al., 2013; Heitzer et al., 2015). Liquid biopsies can thus inform better treatment decisions 
than traditional tumor biopsies, which do not provide a complete genomic profile 
(Heitzer et al., 2015). This was supported in a recent retrospective study which showed 
traces of resistant EGFR T790M in ctDNA samples of 31% of patients who tested 
negative for this mutation on tumor biopsy. One drawback to resistance monitoring using 
ctDNA analysis is the possibility of false negatives, in which case tumor biopsy is still 
currently warranted (Oxnard et al., 2016). More multicenter studies on ctDNA 
genotyping will be necessary to determine the extent of its routine use in future treatment 
regimens (Heitzer et al., 2015). ctDNA analysis will also likely be a useful tool in the 
early detection of recurrence after surgical resection, as imaging techniques simply do not 
have the capacity to detect residual tumor cells (Butler, Spellman, & Gray, 2017). By the 
time recurrence would be visible by imaging, the tumor will likely have already matured 
greatly in terms of genetic diversity and potential TKI-resistant aberrations. Earlier 
detection could lead to earlier implementation of appropriate targeted therapy at a more 
immature point in clonal evolution. In contrast, the value of ctDNA analysis in the early 
detection of primary disease has yet to be determined. This is mostly due to the very 
small amount of ctDNA present in early stages, as its circulating level increases with 
stage and extent of metastasis. Future research should center on improving the reliability 
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and sensitivity of ctDNA analysis so it may serve as a viable tool for detection at any 
stage (Butler et al., 2017). 
Given the relative certainty of acquired resistance with TKIs, it is likely that 
resistance mechanisms will continue to push back on the progress of targeted therapy and 
pose a challenge to discovering a curative strategy. However, the significant increase in 
PFS from traditional cytotoxic chemotherapy and the continued rise in PFS with next-
generation TKIs is encouraging and supports the value in identifying, preventing, and 
overcoming these resistance mechanisms in future research (Herbst et al., 2018). 
Considering the current state of LUAD precision therapy and the ongoing battle 
against resistance, a curative strategy is not likely to be identified soon. Future research 
needs to continue focusing on elucidating resistance mechanisms and developing next-
generation TKIs which target those resistant mutations. It is also worth the continued 
effort to identify novel oncogenic drivers so outcomes can improve for the 26% of 
patients who have yet to be associated with a specific molecular target (Mark G. Kris et 
al., 2014; Shi et al., 2016). For many of the drugs directed against less frequent targets, 
more clinical trials are necessary in order for their potential benefit to be further 
characterized.  
 With the success of immunotherapy in the treatment of PD-L1-positive patients, it 
is possible that combinations of ICBs, chemotherapies, and/or TKIs may bring us closer 
to a curative strategy. Combination regimens have already shown promising results, so 
continued research in this field is absolutely warranted (Langer, Gadgeel, et al., 2016; 
Seto et al., 2014). Immunotherapy is also the most likely and immediate answer for those 
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patients with oncogenic drivers that have not experienced as much success in TKI trials 
(Reck et al., 2016). 
 Precision therapy is an exciting new realm of medicine which has significantly 
influenced the therapeutic experience of patients with LUAD. Hopefully, with continued 
discovery of more oncogenic drivers, more specific TKIs, and optimized combined 
therapies, future LUAD may be treated with the intent to cure.  
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